Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.
about
Epigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated HepatocarcinogenesisBurden of hepatocellular carcinoma among hispanics in South Texas: a systematic review.Irreversible electroporation in primary and metastatic hepatic malignancies: A review.Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010High cancer mortality for US-born Latinos: evidence from California and TexasPrognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based studyProjections of primary liver cancer to 2030 in 30 countries worldwide.Ambient ultraviolet radiation exposure and hepatocellular carcinoma incidence in the United States.Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based studyAdiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort.Disparities in liver cancer occurrence in the United States by race/ethnicity and state.Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma.Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population.Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population.Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies.Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.Ambient PM2.5 air pollution exposure and hepatocellular carcinoma incidence in the United States.Hepatocellular carcinoma disguised as liver abscesses.Circadian misalignment and hepatocellular carcinoma incidence in the United StatesFrontiers in Gastrointestinal Oncology: Advances in Multi-Disciplinary Patient Care.AASLD guidelines for the treatment of hepatocellular carcinomaCurrent frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapyIncreased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated DisadvantageUpdate in global trends and aetiology of hepatocellular carcinoma
P2860
Q26739018-5B128091-20B4-4F05-9DF4-5D07A5B2FE02Q30234676-C1254336-22CC-48DF-B7EC-A4E571C3BA21Q33627010-A3C7AB86-8495-4CD4-80AE-F4DFDE1B7214Q33696050-86838AAB-AE4F-4C41-9B61-73ABC0C5F817Q33892881-F483F986-8CF9-4905-B1F7-01027C662E79Q37698565-A11A8C5D-DB60-46B4-8F5C-095A45F9DE47Q38634903-ECEE048D-52FC-4CCD-80AE-831289C3F06BQ38640277-FDA37DF4-8A81-4FF8-9CAD-2796177A1656Q38640503-473CFBBB-0710-47E8-AEBC-F6D460D44BA5Q38730180-ACEF8E6E-5C14-4181-9A87-D1817625E3E4Q38741005-D9B07133-2A40-4B32-BDD0-E35523221F63Q40070722-059BD1D1-5B56-439A-9BED-6A07C5CCD519Q40439753-30EA7E87-974A-4997-875A-E7328B9B47FFQ41921861-C0578D0F-FD4C-4D15-ADB4-BD8C39044418Q41923187-49A43302-FD17-4BAE-BCFB-DDE95312DE10Q41939869-64E6440F-F882-4E47-AD27-BE952FA196D2Q41991379-5478CF9D-F177-4BE5-AD49-50875F10471FQ47108754-5403B131-E05C-4473-99EC-024DC4BC0F91Q47109489-3487E34A-C849-4E6A-937F-EF34323DDA05Q47185810-3D432DE8-F4C7-4523-B060-9C48D0CFDB49Q47210863-81FB6192-C13C-4B81-8999-9AE18D991DADQ47915968-717E8308-BA01-4457-9335-5191ED11E6BCQ48274382-21BFB7E8-AB09-45E2-B409-E79B2E2F0272Q50249485-4954157F-F022-46E7-B151-BEAE7B8AD532Q52562301-A66F8540-204D-4B58-9CA5-DF8BEE95300CQ52715810-C1D7009D-CE7B-45E0-A6FE-517FAF07C2DBQ55016397-9C2C0C70-5A63-4A6C-956D-0B1146543F0EQ55717557-5EA191E3-A549-4B5E-A4DD-74729DD85D0CQ56172239-667B2C4B-F39A-43C8-8C87-9CD9F64BAF8FQ58117622-58E13E56-C64F-4B06-A802-13A8A25DA501Q58750606-5BE591DA-56D8-45CA-887A-B650A5755F5AQ59136659-9085274E-C989-4826-8470-EA3BEBF4D97E
P2860
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Population attributable fracti ...... arcinoma in the United States.
@en
Population attributable fracti ...... arcinoma in the United States.
@nl
type
label
Population attributable fracti ...... arcinoma in the United States.
@en
Population attributable fracti ...... arcinoma in the United States.
@nl
prefLabel
Population attributable fracti ...... arcinoma in the United States.
@en
Population attributable fracti ...... arcinoma in the United States.
@nl
P2093
P2860
P356
P1433
P1476
Population attributable fracti ...... carcinoma in the United States
@en
P2093
Austin G Duffy
Barry I Graubard
Katherine A McGlynn
Oxana V Makarova-Rusher
Sean F Altekruse
Tim F Greten
Tim S McNeel
P2860
P304
P356
10.1002/CNCR.29971
P407
P577
2016-03-21T00:00:00Z